SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non-small cell lung cancer
العنوان: | SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non-small cell lung cancer |
---|---|
المؤلفون: | Yunjian Pan, Jing Li, Xiao Ma, Wuzhang Wang, Lifang Zhao, Wenjie You, Li Liu |
المصدر: | International Journal of Oncology |
بيانات النشر: | D.A. Spandidos, 2020. |
سنة النشر: | 2020 |
مصطلحات موضوعية: | 0301 basic medicine, Male, Cancer Research, Lung Neoplasms, Carcinogenesis, Cell, Apoptosis, Kaplan-Meier Estimate, migration, 0302 clinical medicine, Cell Movement, Carcinoma, Non-Small-Cell Lung, Lung, Articles, Cell cycle, Middle Aged, invasion, Prognosis, Up-Regulation, Gene Expression Regulation, Neoplastic, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Gene Knockdown Techniques, Female, cisplatin resistance, medicine.drug, Transcriptional Activation, proliferation, Antineoplastic Agents, Biology, 03 medical and health sciences, Downregulation and upregulation, Cell Line, Tumor, medicine, Humans, Neoplasm Invasiveness, Lung cancer, neoplasms, non-small cell lung cancer, Cell Proliferation, Cisplatin, Oncogene, Cell growth, Cancer, SET and MYND domain-containing protein 3, Histone-Lysine N-Methyltransferase, medicine.disease, respiratory tract diseases, 030104 developmental biology, Drug Resistance, Neoplasm, Cancer research, prognostic marker |
الوصف: | SET and MYND domain‑containing protein 3 (SMYD3) is a lysine methyltransferase, and its aberrant expression has been implicated in several malignancies. However, its clinical and biological roles in non‑small cell lung cancer (NSCLC) remain unclear. In the present study, it was revealed that SMYD3 was significantly upregulated in NSCLC tissues, as compared with paired adjacent normal tissues. A high SMYD3 expression was associated with aggressive clinicopathological characteristics, as well as poor disease‑free survival and overall survival (OS) in NSCLC patients. Multivariate analysis revealed that SMYD3 overexpression was an independent predictor of poor OS in NSCLC patients. In addition, SMYD3 knockdown inhibited cell proliferation, triggered apoptosis, and blocked migration and invasion in NSCLC cells in vitro, whereas stable SMYD3 overexpression promoted NSCLC cell proliferation. Furthermore, the SMYD3‑silenced NSCLC cells became more sensitive, whereas the SMYD3‑overexpressed NSCLC cells became more resistant to the apoptosis induced by cisplatin. Mechanistic analysis revealed that SMYD3 knockdown led to the upregulation of Bim, Bak and Bax, and the downregulation of Bcl‑2, Bcl‑xl, MMP‑2 and MMP‑9 in NSCLC cells. In combination, the present findings indicated that SMYD3 has oncogenic potential in the context of NSCLC, providing evidence that may be exploited for both prognostic and therapeutic purposes in the future. |
اللغة: | English |
تدمد: | 1791-2423 1019-6439 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a99d741498a5b43dc64ad5801d1fea0 http://europepmc.org/articles/PMC7384847 |
Rights: | OPEN |
رقم الانضمام: | edsair.doi.dedup.....6a99d741498a5b43dc64ad5801d1fea0 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 17912423 10196439 |
---|